iBio, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-33.0M | $-18.4M | $-24.9M | $-65.0M | $-50.3M | $-23.2M | $-16.4M | $-17.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | $179.0K |
| Depreciation | $558.0K | $484.0K | $638.0K | $674.0K | $2.3M | $472.0K | $282.0K | $1.4M |
| Amortization | $20.0K | $20.0K | $20.0K | $126.0K | $401.0K | $291.0K | $298.0K | $322.0K |
| Stock-Based Compensation | $1.4M | $1.5M | $2.0M | $4.4M | $4.4M | $1.6M | $388.0K | $241.0K |
| Net Cash from Operating Activities | $-23.2M | $-15.3M | $-18.6M | $-30.4M | $-37.5M | $-30.1M | $-13.3M | $-14.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $578.0K | $16.0K | $210.0K | $5.7M | $7.3M | $4.9M | $1.1M | $920.0K |
| Business Acquisitions | — | — | — | $692.0K | — | — | — | — |
| Net Cash from Investing Activities | $-32.0M | $742.0K | $906.0K | $7.0M | $-5.1M | $-26.5M | $-1.2M | $-990.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $103.0M | $8.9M | $24.5M | $2.3M | $-6.1M | $78.8M | $65.2M | $3.5M |
| Net Change in Cash | $47.8M | $-5.6M | $6.8M | $-21.1M | $-48.7M | $22.3M | $50.7M | $-11.5M |
| Free Cash Flow | $-23.8M | $-15.3M | $-18.8M | $-36.2M | $-44.8M | $-35.0M | $-14.4M | $-14.9M |